 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ZyVersa Therapeutics GAAP EPS of -$0.09...

ZyVersa Therapeutics GAAP EPS of -$0.09

Key Corporate Highlights: Progressing toward Q1-2024 initiation of a proof-of-concept clinical trial with Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease...

ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract affecting 1 in 100 Americans (around 2.4 million people) that can lead to disabling bowel symptoms and...

ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model

Despite decades of effective environmental policy and improved air quality in the US, air pollution remains the greatest environmental health risk factor, contributing to 100,000 to 200,000...

ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation

ZyVersa Therapeutics files to sell its units...

ZyVersa Therapeutics files to sell its units

Molecular Neurobiology publication demonstrated that NLRP3 inflammasomes have an important role in the pathogenesis of multiple sclerosis ( MS ) based on significant decreases in neuronal damage and...

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Paper reports that obesity exacerbates scarring of the heart's muscular tissue (myocardial fibrosis) through recruitment of inflammasome ASC to the heart's mitochondria, facilitating NLRP3...

ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

Chronic kidney disease is most common in people 65 years and older.NLRP3 inflammasomes signaling in the kidneys' filtration system ( glomerular podocytes ) occurs as early as middle age, leading to...

ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function

This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and progression of chronic kidney disease (CKD).ZyVersa's...

ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200's Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease

The paper, published in Pharmaceuticals, demonstrates that pyrin inflammasome-mediated inflammation induced by traumatic brain injury (TBI) contributes to cardiovascular co-morbidities through...

ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It leverages advanced & proprietary technologies to develop product candidates in the areas of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

Watchers	4,359
52-Wk Low	$0.0651
52-Wk High	$14.95

Market Cap	$3.59M
Volume (M)	5.61M
52-Wk High	$14.95
52-Wk Low	$0.0651

ZVSA ZyVersa Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals